Holen Sie sich die Stockscreener-App
13.99
0.29%
-0.04
Schlusskurs vom Vortag:
$14.03
Offen:
$13.99
24-Stunden-Volumen:
79,158
Relative Volume:
0.37
Marktkapitalisierung:
$535.60M
Einnahmen:
$25.42M
Nettoeinkommen (Verlust:
$-143.75M
KGV:
-4.0307
EPS:
-3.4709
Netto-Cashflow:
$-129.55M
1W Leistung:
-2.30%
1M Leistung:
+10.24%
6M Leistung:
+126.01%
1J Leistung:
+77.76%
1-Tages-Spanne:
$13.74
$14.24
1-Wochen-Bereich:
$13.34
$14.49
52-Wochen-Spanne:
$4.93
$14.49
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
13.99 | 537.13M | 25.42M | -143.75M | -129.55M | -3.4709 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-11 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week HighShould You Buy? - MarketBeat
Sell Signal: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Buyback Activity & Long-Term Safe Investment Plans - baoquankhu1.vn
How Entrada Therapeutics Inc. (TRDA) Affects Rotational Strategy Timing - Stock Traders Daily
Entrada Therapeutics, Inc. $TRDA Stock Holdings Increased by JPMorgan Chase & Co. - MarketBeat
Investment Report: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
TRDA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Investor Mood: Does Entrada Therapeutics Inc have declining or rising EPS2026 AllTime Highs & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Entrada Therapeutics : Corporate Presentation April 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says - marketscreener.com
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating - marketscreener.com
TRDA PE Ratio & Valuation, Is TRDA Overvalued - Intellectia AI
Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock - marketbeat.com
Insider Sell Alert: Kory Wentworth Sells Shares of Entrada Thera - GuruFocus
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock By Investing.com - Investing.com Canada
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock - Investing.com
Entrada Therapeutics (TRDA) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
(TRDA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TRDA (NASDAQ: TRDA) insider 10b5‑1 sales listed, 11,388-share trade noted - Stock Titan
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Cantor Fitzgerald Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-03-31 23:31:11 - baoquankhu1.vn
Risk Analysis: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc still a buy after recent gains2026 Retail & Capital Efficient Trade Techniques - baoquankhu1.vn
Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Big Picture: Can Entrada Therapeutics Inc deliver consistent EPS growthTrade Analysis Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail
Hedge Fund Bets: Can Entrada Therapeutics Inc outperform under higher oil prices2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA) - Stock Titan
Responsive Playbooks and the TRDA Inflection - Stock Traders Daily
Gainers Report: Can Entrada Therapeutics Inc ride the EV wave2026 Sector Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc benefiting from innovation trends2026 Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug EndMonth: How does Entrada Therapeutics Inc compare to its peersPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Trading Recap: Will Entrada Therapeutics Inc benefit from rising consumer demandGlobal Markets & Verified Momentum Stock Watchlist - baoquankhu1.vn
Harmony Biosciences (NASDAQ:HRMY) and Entrada Therapeutics (NASDAQ:TRDA) Critical Review - Defense World
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) COO Sells 3,116 Shares of Stock - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 5,089 Shares - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 11,388 Shares - MarketBeat
Entrada Therapeutics (TRDA) CFO sells 16,477 shares under 10b5-1 plan - Stock Titan
Understanding the Setup: (TRDA) and Scalable Risk - Stock Traders Daily
Entrada Therapeutics (NASDAQ:TRDA) Hits New 1-Year HighTime to Buy? - MarketBeat
Kory Wentworth sells TRDA shares via 10b5-1 plan (TRDA) reported to SEC - Stock Titan
Aug Breakouts: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Gainers & Entry Point Confirmation Alerts - baoquankhu1.vn
Aug Volume: How does Entrada Therapeutics Inc compare to its peersJuly 2025 Final Week & Precise Buy Zone Identification - baoquankhu1.vn
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kory James Wentworth Sells 7,988 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):